IPT for major depression following perinatal loss

The Healing After Loss (HeAL) Study, a protocolized, fully powered randomized controlled trial testing the efficacy of group interpersonal psychotherapy (IPT) for women experiencing major depressive disorder (MDD) following perinatal loss. The trial responds to a critical and understudied clinical need: perinatal loss (including early and late fetal death and early neonatal death) is associated with substantially elevated rates of MDD and post-traumatic stress disorder (PTSD), unique treatment challenges, and distinct patterns of grief and social isolation. Building on prior pilot work that produced the first manualized IPT approach tailored to psychiatric disorders after perinatal loss, this study will evaluate group IPT specifically adapted for perinatal loss against an active comparison condition, group coping with depression.

The study plans to recruit a sample of 274 women from the Flint and Detroit areas in Michigan who meet criteria for a major depressive episode following a perinatal loss. Participants will be randomized either to the IPT intervention for perinatal loss or to the group coping with depression condition. Assessments are scheduled at baseline, mid-treatment (8 weeks), post-treatment (16 weeks), and follow-up (28 weeks), allowing the trial to evaluate both short-term and sustained effects of the intervention. The primary clinical outcome is time to recovery from the major depressive episode. Secondary clinical outcomes include depressive symptom severity, PTSD symptoms, and time to recovery from PTSD. The protocol also assesses additional domains that are particularly relevant to bereavement and parental functioning: social support, social role functioning (including parental functioning for participants with living children), overall well-being, grief (including complicated grief and fault beliefs), and fear of subsequent pregnancies.

The trial explicitly hypothesizes that IPT's impact on time to recovery from MDD may be mediated by improvements in social support and reductions in grief-related processes. The study design emphasizes rigor and reproducibility through randomization, clear inclusion criteria, validated outcome measures, blinded outcome raters, manualized treatment protocols, fidelity assessments, and transparent power and statistical analyses. The protocol highlights strengths including the focus on populations disproportionately affected by perinatal loss, particularly African-American women and socioeconomically disadvantaged women, thereby increasing the study's relevance to disparity populations. The research team acknowledges potential recruitment challenges, especially during the context of a global pandemic and within communities that may harbor research mistrust or greater mental health stigma, and outlines ethical oversight: institutional review board approval, a data and safety monitoring board, community partner ethics review submission, and procedures to protect confidentiality and monitor adverse events.

The protocol states intentions for dissemination to research and clinical communities, recruitment partner organizations, and study participants, and indicates that deidentified datasets will be available through the National Institute of Mental Health Data Archive and to qualified investigators on request. Registered as trial NCT04629599, the HeAL Study aims to produce definitive evidence about the efficacy of IPT for MDD following perinatal loss and to inform clinical approaches for a population whose mental health needs have historically received limited rigorous intervention research.